Lexicon Pharmaceuticals, Inc. (LXRX) News
Filter LXRX News Items
LXRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LXRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LXRX News From Around the Web
Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million […] |
Lexicon Appoints Scott Coiante as Chief Financial OfficerTHE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Ag |
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%Key Insights Lexicon Pharmaceuticals' significant private equity firms ownership suggests that the key decisions are... |
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)Confirms Previously Disclosed and Anticipated FDA DecisionTHE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the |
Lexicon completes subject enrolment for DPNP trial of LX9211The trial’s top-line data is anticipated in the first quarter of next year. |
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripher |
Lexicon Pharmaceuticals to Participate in December Investor ConferencesTHE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December. Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET Simultaneous webcasts will |
Lexicon Pharmaceuticals to Cut 60% of WorkforceLexicon Pharmaceuticals to Cut 60% of Workforce |
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDAImplementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP, HCM and Obesity Efforts Expected to Reduce 2025 Operating Costs by $100 Million Conference Call and Webcast at 9:00 am ET THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its comme |
Lexicon to disband sales team, lay off 60% of staffThe restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista. |